ArticleFrontiers in immunology2025
Vancomycin is a risk factor for acute pancreatitis and increases the mortality rate in patients with severe pancreatitis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the later stages of severe acute pancreatitis, serious infections often occur, leading to a worse prognosis. Vancomycin is beneficial for controlling infections, but it has hepatotoxic and nephrotoxic effects. Methods: Data regarding the toxic side effects of vancomycin were obtained from the FDA Adverse Event Reporting System (FAERS), and animal experiments were conducted to validate these findings.Clinical data of patients with severe pancreatitis were extracted from the MIMIC database. Subsequently, the survival and matching packages were utilized to perform propensity score matching to assess the impact of vancomycin on patient prognosis. Finally, the mediation package was employed to analyze the clinical factors that mediate the effect of vancomycin on prognosis. Results: Data from the FAERS database and animal studies suggest that vancomycin may harm pancreatic tissue. Consequently, the administration of vancomycin in patients with severe pancreatitis increases their risk of mortality. In the Intensive Care Unit (ICU), the mediation effects of potassium, total bilirubin, hemoglobin, age, and lactate on the relationship between vancomycin use and prognosis in severe pancreatitis were found to account for 7.07%, 5.58%, 6.51%, 16.68%, and 10.37% of the total effect, respectively. Furthermore, during the 28 days prior to ICU admission, the mediation effects of age, hemoglobin, red cell distribution, hematocrit, CO2 concentration, urea nitrogen, levofloxacin, creatinine, and heart failure accounted for 18.47%, 10.39%, 13.63%, 6.69%, 5.74%, 20.07%, 7.39%, -66.04%, and 6.82% of the total effect, respectively, concerning the same variables. Conclusion: Vancomycin may induce pancreatic injury and elevate the risk of mortality in patients with severe pancreatitis. Moreover, renal function, patient age, heart failure, and red blood cell-related indicators are significant mediating factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.